A potential blood test can distinguish ME/chronic fatigue syndrome with great accuracy, after years of medical uncertainty.

HOUSTON, TEXAS / ACCESS Newswire / January 20, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a SmellTech platform company digitizing scent as a native data language for ar ...

New research could allow health care providers to identify and treat patients at risk for rheumatoid arthritis before the ...

The AACE has updated its guidance on obesity and adiposity-based chronic disease to reflect a focus on improving overall ...

Novartis received breakthrough therapy designation from the FDA for ianalumab, a monoclonal antibody aimed at treating Sjögren’s disease. Ianalumab works by depleting B cells and blocking BAFF-R ...

Oncology pharmacists bridge gaps in test ordering, result interpretation, and therapy access, ensuring timely and effective ...

People with from spinal cord injuries often lose some or all their limb function. In most patients, the nerves in their limbs work fine, and the neurons in their brain are still operational, but the ...

The autoimmune diagnostic company expects its new assay to be available by the end of this year or in early 2027.

PECOTA, which stands for Player Empirical Comparison and Optimization Test Algorithm, is BP’s proprietary system that projects player and team performance PECOTA is a system that takes a player’s past ...